Previous close | 398.81 |
Open | 399.55 |
Bid | 383.60 x 100 |
Ask | 385.04 x 100 |
Day's range | 383.23 - 400.59 |
52-week range | 327.73 - 550.76 |
Volume | |
Avg. volume | 263,778 |
Market cap | 22.836B |
Beta (5Y monthly) | 0.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy underperformed the Russell Midcap Growth Index and returned 13.66% (gross) and 13.44% (net) while the index return was -14.55%. In addition, please check […]
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.